Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
Our study comprehensively revealed the safety characteristics of osimertinib-associated myotoxicity. The results would offer referable evidence on the safety and prognosis of osimertinib.
Authors
- Qi Song (ORCID: https://orcid.org/0000-0001-8446-5910)
- Yaqian Tan
Institutions
- Guangzhou Psychiatric Hospital (CN)
- Guangzhou Medical University Cancer Hospital (CN)
- Guangdong 999 Brain Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1186/s12885-025-14743-3
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Project
- Basic and Applied Basic Research Foundation of Guangdong Province